EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Meet in the middle: Could cell mediated‐immunity assays be the answer for ideal Cytomegalovirus prophylaxis after lung transplantation? Observational study from a single center with intermittent antiviral prophylaxis

Sílvia Vidal Campos iD, Lisete Ribeiro Teixeira iD, Maristela Pinheiro Freire iD, Ana Carolina Mamana iD, Clarisse Martins Machado iD

Transplant Infectious Disease · 2024

DOI: 10.1111/tid.14198 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Sílvia Vidal Campos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Division, Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Lung Transplantation, Cytomegalovirus Infections, Antiviral Agents, Cytomegalovirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) can cause tissue‐invasive disease and indirect effects after lung transplantation (LTx) such as acute rejection episodes and chronic lung allograft dysfunction. Monitoring CMV‐specific cell immune recovery (CMV‐CIR) after LTx can individualize CMV risks and establish better antiviral approach. This study evaluated the dynamics of CMV‐CIR, using QuantiFERON‐CMV assay (Qiagen Group), in the first year after LTx.

Methods

Prospective observational cohort study included lung transplant recipients from December/2015 to December/2016. Universal antiviral prophylaxis with intravenous ganciclovir 5 mg/kg/day 3 days/week for 3 months was given for CMV‐seropositive recipients (R+) and only CMV‐seropositive donor and negative recipient (D+/R−) received a 6‐month‐prophylaxis with ganciclovir and valganciclovir, on alternate days, in the first 3 months and then, 3 more months of valganciclovir. QuantiFERON‐CMV was measured at the same time points of surveillance bronchoscopies. CMV infection was defined as any DNAemia detected and CMV disease with proven biopsy or antigenemia pp65 above 10 cells/300.000 neutrophils.

Results

Thirty‐eight patients were included. On days 45, 90, and 365 days post‐LTx, 60%, 72%, and 81% QuantiFERON‐CMV were reactive, respectively. Eleven patients (28.9%) presented CMV‐disease and 27 DNAemia/CMV infections. Reactive tests were able to predict CMV disease only at 90 days after LTx ( p = .027) but failed on DNAemia/CMV infection ( p = .148). Daily prophylaxis, for D+/R− patients (13.2%), remained as an independently associated factor for not achieving reactive QuantiFERON‐CMV (adjusted OR .27, 95%CI .12–.60, p = .02).

Conclusion

QuantiFERON‐CMV may be another diagnostic tool to help stratify CMV‐disease risk and individualized antiviral prophylaxis after LTx. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationCytomegalovirus InfectionsAntiviral AgentsCytomegalovirusGanciclovirImmunity, CellularValganciclovirHumansMaleMiddle AgedFemaleProspective StudiesAdultAgedTransplant Recipients

Stichwörter der Autor:innen

cellular immunitycytomegalovirusinterferonslung transplantationprophylaxis

Substanzen

Antiviral AgentsGanciclovirValganciclovir

Autor:innen und Institutionen

  • Pulmonary Division, Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil.
  • Infection Control Team, Clinical Hospital, University of Sao Paulo, Sao Paulo, Brazil.
  • Virology Laboratory (LIM 52 HCFMUSP), Institute of Tropical Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil.

ORCID-Profile: Sílvia Vidal Campos, Lisete Ribeiro Teixeira, Maristela Pinheiro Freire, Ana Carolina Mamana, Clarisse Martins Machado

Förderung

  • Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP)

Zitieren

APA

Campos, S. V., Teixeira, L. R., Freire, M. P., Mamana, A. C., & Machado, C. M. (2024). Meet in the middle: Could cell mediated‐immunity assays be the answer for ideal Cytomegalovirus prophylaxis after lung transplantation? Observational study from a single center with intermittent antiviral prophylaxis. Transplant Infectious Disease. https://doi.org/10.1111/tid.14198

Vancouver

Campos SV, Teixeira LR, Freire MP, Mamana AC, Machado CM. Meet in the middle: Could cell mediated‐immunity assays be the answer for ideal Cytomegalovirus prophylaxis after lung transplantation? Observational study from a single center with intermittent antiviral prophylaxis. Transplant Infectious Disease. 2024. doi:10.1111/tid.14198

BibTeX
@article{Campos2024,
  author = {Campos, Sílvia Vidal and Teixeira, Lisete Ribeiro and Freire, Maristela Pinheiro and Mamana, Ana Carolina and Machado, Clarisse Martins},
  title = {Meet in the middle: Could cell mediated‐immunity assays be the answer for ideal Cytomegalovirus prophylaxis after lung transplantation? Observational study from a single center with intermittent antiviral prophylaxis},
  journal = {Transplant Infectious Disease},
  year = {2024},
  doi = {10.1111/tid.14198}
}
Kostenlos starten →